Risk Factors for Metachronous Gastric Cancer in the Remnant Stomach After Early Cancer Surgery

2010 ◽  
Vol 34 (7) ◽  
pp. 1548-1554 ◽  
Author(s):  
Isao Nozaki ◽  
Junichirou Nasu ◽  
Yoshiro Kubo ◽  
Minoru Tanada ◽  
Rieko Nishimura ◽  
...  
Gut and Liver ◽  
2021 ◽  
Author(s):  
Yonghoon Choi ◽  
Nayoung Kim ◽  
Hyuk Yoon ◽  
Cheol Min Shin ◽  
Young Soo Park ◽  
...  

2013 ◽  
Vol 17 (1) ◽  
pp. 61-66 ◽  
Author(s):  
Isao Nozaki ◽  
Shinji Hato ◽  
Takaya Kobatake ◽  
Koji Ohta ◽  
Yoshirou Kubo ◽  
...  

2019 ◽  
Vol 19 (4) ◽  
pp. 417
Author(s):  
Young-Won Lee ◽  
Amy Kim ◽  
Minkyu Han ◽  
Moon-Won Yoo

Medicine ◽  
2019 ◽  
Vol 98 (32) ◽  
pp. e16739
Author(s):  
Jung Ho Kim ◽  
Jinnam Kim ◽  
Woon Ji Lee ◽  
Hye Seong ◽  
Heun Choi ◽  
...  

2015 ◽  
Vol 29 (6) ◽  
pp. 321-325 ◽  
Author(s):  
Takafumi Sugimoto ◽  
Yutaka Yamaji ◽  
Kosuke Sakitani ◽  
Yoshihiro Isomura ◽  
Shuntaro Yoshida ◽  
...  

BACKGROUND: Endoscopic submucosal dissection (ESD) of early gastric cancer is a minimally invasive procedure. However, the risk for metachronous cancers after successful cancer treatment remains high and the risk factors for metachronous cancers have not been elucidated.OBJECTIVE: To evaluate the risk factors for metachronous gastric cancers after ESD with a long-term follow-up.METHODS: A total of 155 consecutive patients (119 men, 36 women, mean age 68.9 years) were treated with ESD between September 2000 and September 2009. Biopsy specimens were obtained from the greater curvature of the antrum and middle corpus to evaluate gastric mucosal status, includingHelicobacter pylori, intestinal metaplasia (IM) and neutrophil infiltration (NI) before ESD. Follow-up endoscopy after ESD was scheduled at two and six months, one year and annually thereafter.H pylorieradication was recommended when possible.RESULTS: The median follow-up period was 4.2 years. Metachronous gastric cancers were found in 23 of 155 patients (3.5% per year). No local recurrences were observed. The cumulative incidence of metachronous gastric cancer was significantly high in IM and NI in the corpus (P=0.0093 and P=0.0025, respectively [log-rank test]). The ORs for IM and NI in the corpus were 2.65 and 3.06, respectively, according to the Cox proportional hazards model (P=0.024 and P=0.0091, respectively).CONCLUSIONS: The presence of IM and NI in the corpus was closely related to the development of metachronous gastric cancer after ESD.


2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 120-120
Author(s):  
Tsutomu Sato ◽  
Toru Aoyama ◽  
Yukio Maezawa ◽  
Kazuki Kano ◽  
Kenki Segami ◽  
...  

120 Background: Our previous study clarified that morbidity was a negative prognostic factor and sarcopenia defined by of the handgrip strength was a risk factor for the morbidity in gastric cancer surgery. Sarcopenia was reportedly a negative prognostic factor in colorectal cancer, hepatocellular carcinoma and malignant melanoma. This study aimed to evaluate impact of preoperative sarcopenia on recurrence-free survival (RFS) in gastric cancer surgery. Methods: Between May 2011 and June 2013, 256 consecutive primary gastric cancer patients who underwent curative surgery were retrospectively examined. Patients who received neoadjuvant chemotherapy or were diagnosed with pathological stage IV were excluded. Preoperative skeletal muscle mass was evaluated by bioelectrical impedance analysis and was expressed as skeletal muscle index or SMI (muscle mass/height2) by adjusting absolute muscle mass with height. Preoperative muscle function was measured by hand grip strength (HGS). Each cutoff value was determined as the gender-specific lowest 20% of the distribution of each measurement. Univariate and multivariate analyses were preformed to identify risk factors for RFS using a Cox proportional hazards model. Results: Median age (range) was 66 years (37-85 years). Male to female ratio was 168:88. Median follow-up period was 33.4 months. Pathological stage was I in 160, II in 48 and III in 48 patients. Univariate analysis showed that age, adjuvant chemotherapy, pT, pN, histological type, tumor size, total gastrectomy, low SMI and low HGS were significant risk factors for RFS. Multi-variate Cox’s proportional hazard analyses demonstrated that pT (HR 2.76, p = 0.0001), pN (HR 1.375, p = 0.037), histological type (HR 3.46, p = 0.014), low SMI (HR2.17, p = 0.036) were the significant risk factors for RFS. The three-year RFS was 89.1% in the patients with high SMI and 73.2% in those with low SMI (p = 0.007). Conclusions: Low SMI was an independent risk factor for RFS in Stage I-III gastric cancer. Low HGS, a risk factor for morbidity shown in our previous study, was not a risk independent factor for RFS. Preoperative sarcopenia as the short- and long-term outcomes has a value to be tested in the future prospective studies in gastric cancer surgery.


Author(s):  
Youn I Choi ◽  
Jun-Won Chung

The role of <i>Helicobacter pylori</i> (<i>H. pylori</i>) eradication in patients undergoing gastrectomy for gastric cancer is unclear. Although European and Asian guidelines strongly recommend <i>H. pylori</i> eradication in patients who undergo endoscopic resection for early gastric cancer, these guidelines do not specify the tests useful for diagnosing <i>H. pylori</i> infection, the optimal timing and appropriate eradication regimens, and follow-up strategies in patients undergoing gastrectomy for gastric cancer. This review aims to update the guidelines for the diagnosis and management of <i>H. pylori</i> infection in patients undergoing gastrectomy for gastric cancer. We have focused on the following issues: 1) diagnostic tests for <i>H. pylori</i> infection in the remnant stomach, 2) optimal timing and regimen for <i>H. pylori</i> eradication, and 3) role of <i>H. pylori</i> eradication in reducing the risk of metachronous gastric cancer in the remnant stomach.


Sign in / Sign up

Export Citation Format

Share Document